Mg217 Psoriasis Ointment
NDC 68093-7233
Product Information
Mg217 Psoriasis (coal tar) is a OTC MONOGRAPH DRUG-approved product labeled by Wisconsin Pharmacal Company. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a ointment for topical administration. This product entry covers the primary NDC 68093-7233 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 68093-7233?
What are the uses of this product?
What are Active Ingredients of this product?
- COAL TAR .03 g/g - A by-product of the destructive distillation of coal used as a topical antieczematic. It is an antipruritic and keratoplastic agent used also in the treatment of psoriasis and other skin conditions. Occupational exposure to soots, tars, and certain mineral oils is known to be carcinogenic according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985) (Merck Index, 11th ed).
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- COAL TAR (UNII: R533ESO2EC)
- COAL TAR (UNII: R533ESO2EC) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- BIS-DIGLYCERYL POLYACYLADIPATE-2 (UNII: 6L246LAM9T)
- CHOLECALCIFEROL (UNII: 1C6V77QF41)
- PETROLATUM (UNII: 4T6H12BN9U)
- .ALPHA.-TOCOPHEROL, D- (UNII: N9PR3490H9)
- GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)
- ALKYL (C12-15) BENZOATE (UNII: A9EJ3J61HQ)
- PEG/PPG-18/18 DIMETHICONE (UNII: 9H0AO7T794)
- PEG-100 STEARATE (UNII: YD01N1999R)
- VITAMIN A PALMITATE (UNII: 1D1K0N0VVC)
* Please review the full disclaimer at the bottom of this page.